
    
      A prospective, randomized, multicenter, open-label study to compare the efficacy and safety
      of simplifying from a regimen of atazanavir (ATV) + ritonavir (RTV) + tenofovir/emtricitabine
      (TDF/FTC) to ATV + abacavir sulfate/lamivudine (ABC/3TC) without RTV for 48 weeks in
      virologically suppressed, HIV-1 infected, HLA-B*5701 negative subjects.

      ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of
      updating systems to reflect the change in sponsorship.
    
  